跳转至内容
Merck
CN

Q0632

Quinapril hydrochloride

≥98% (HPLC), solid

别名:

(3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C25H30N2O5 · HCl
化学文摘社编号:
分子量:
474.98
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Quinapril hydrochloride, ≥98% (HPLC), solid

InChI key

IBBLRJGOOANPTQ-JKVLGAQCSA-N

SMILES string

Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3ccccc3C[C@H]2C(O)=O

InChI

1S/C25H30N2O5.ClH/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30;/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30);1H/t17-,21-,22-;/m0./s1

assay

≥98% (HPLC)

form

solid

color

white

solubility

H2O: >10 mg/mL

storage temp.

2-8°C

Quality Level

Gene Information

human ... ACE(1636)

正在寻找类似产品? 访问 产品对比指南

Application

Quinapril hydrochloride has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on renal tubular epithelial cell proliferation in human renal tubular epithelial cells. It has also been used as an ACE inhibitor to evaluate its effects on the expression of angiotensin II (AII) in patient-derived Atheroma samples.

Biochem/physiol Actions

Quinapril has been studied to exhibit therapeutic effects against hypertension and congestive heart failure.
Quinapril is a short-acting angiotensin converting enzyme (ACE) inhibitor.

pictograms

Health hazard

signalword

Danger

Hazard Classifications

Repr. 2 - STOT RE 1

存储类别

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

A M D Watson et al.
Diabetologia, 53(1), 192-203 (2009-10-29)
There is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular disease. This study aimed to assess the effects of the non-peptidergic endothelin receptor A (ETA) antagonist avosentan in a mouse model of accelerated diabetic nephropathy and
B Daan Westenbrink et al.
Heart (British Cardiac Society), 97(19), 1590-1596 (2011-07-16)
To investigate the association between sustained postoperative anaemia and outcome after coronary artery bypass graft (CABG) surgery. Retrospective analysis of the IMAGINE trial, which tested the effect of the ACE inhibitor quinapril on cardiovascular events after CABG. Thoracic surgery clinic/outpatient
Spyridon Deftereos et al.
The American journal of cardiology, 105(1), 54-58 (2010-01-28)
Angiotensin-converting enzyme inhibitors have been reported to inhibit in-stent restenosis. To assess the effect of angiotensin-converting enzyme inhibition on in-stent restenosis and its relation to apoptosis, 86 patients with chronic coronary artery disease who required stent implantation in the left
Syed T Rahman et al.
Journal of cardiovascular pharmacology and therapeutics, 17(2), 139-145 (2011-07-14)
We sought to determine whether a combination of angiotensin-converting enzyme inhibitors (ACEIs) and the nutraceutical α-lipoic acid (ALA) regulates blood pressure, endothelial function, and proteinuria in diabetic patients with Stage I hypertension. A total of 40 diabetic patients with Stage
Christine R Culy et al.
Drugs, 62(2), 339-385 (2002-01-31)
Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor. Quinapril produces favourable haemodynamic changes, and improves ventricular and endothelial function in patients with various cardiovascular disorders; these effects are mediated

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持